Individuals with initial brain metastases (BMs) who had HER2-positive metastatic BC and whose disease condition worsened after receiving trastuzumab and a taxane benefited significantly from treatment with T-DXd as opposed to T-DM1 [44]. Here, ERBB2 is linked to breast cancer.